Market research
LMNL Liminal BioSciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 28M
- P/E ratio
- Not available
- Analyst target
- 10.16
- Dividend yield
- 0.0%
- Beta
- 29.34
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA53272L1031
- Market cap
- 28M
- P/E ratio
- Not available
- Analyst target
- 10.16
- Dividend yield
- 0.0%
- Beta
- 29.34
About
About Liminal BioSciences Inc
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LMNL discussion.
5 years, 4 months ago
Liminal BioSciences Inc is currently in a long term downtrend where the price is trading 23.4% below its 200 day moving average.
From a valuation standpoint, the stock is 97.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 39.1.
Liminal BioSciences Inc's total revenue sank by 78.9% to $1M since the same quarter in the previous year.
Its net income has increased by 80.7% to $-40M since the same quarter in the previous year.
Finally, its free cash flow grew by 24.3% to $-27M since the same quarter in the previous year.
Based on the above factors, Liminal BioSciences Inc gets an overall score of 3/5.